[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Views 545
Citations 0
News From the Food and Drug Administration
May 3, 2016

New Salvo Against Opioid Abuse

JAMA. 2016;315(17):1826. doi:10.1001/jama.2016.4409

Building on its recent efforts to reverse the US epidemic of opioid abuse, the FDA has issued draft guidance for the pharmaceutical industry to develop generic abuse-deterrent formulations of approved opioid medications.

Last year, the FDA provided the industry with final guidance on developing abuse-deterrent versions of brand-name opioids. “We recognize that abuse-deterrent technology is still evolving and is only 1 piece of a much broader strategy to combat the problem of opioid abuse,” FDA Commissioner Robert Califf, MD, said in a statement (http://1.usa.gov/25nA0QN).

First Page Preview View Large
First page PDF preview
First page PDF preview